A survey of opioid treatment programs finds that the proportion offering on-site testing for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) declined substantially between 2000 and 2011, despite guidelines ...
Tags: opioid treatment programs, human immunodeficiency virus
Rainbow Coral and its joint venture partner, Therakine, have reached a major new milestone in the development of a revolutionary new drug delivery technology. The companies reached terms to initiate Phase II of research and analysis on a ...
Tags: RBCC, Drug Delivery Development
The US Food and Drug Administration (FDA) has approved Orexo's Zubsolv (buprenorphine/naloxone) sublingual tablet CIII for the maintenance treatment of opioid dependence. Indicated for use as part of a complete treatment plan, including ...
Tags: Maintenance Therapy, Medicine
Modern Medical has rolled out its Opioid Defense Manager (ODM) solution in an effort to curb increasing opioid abuse in the workers' compensation industry across the US. Initially introduced in November 2012 in a test phase, the ODM is a ...
American pharmaceutical company BioDelivery Sciences (BDSI) has completed the safety and tolerability trial of BEMA Buprenorphine/Naloxone (BNX), which is indicated for the treatment of opioid dependent patients. BDSI claims that BNX, ...
Tags: BioDelivery Sciences, BEMA Buprenorphine, opioid dependent patients
Braeburn, a subsidiary of Apple Tree Partners, has gained commercialization rights to Titan Pharmaceuticals' long-acting subdermal implant in the US and Canada, under the signed license agreement. The investigational subcutaneous implant, ...
Tags: Braeburn, Marketing Rights, subsidiary of Apple Tree Partners, Medicine
US Food and Drug Administration (FDA) has approved Reckitt Benckiser Pharmaceuticals's Suboxone (buprenorphine and naloxone) sublingual film 4 mg and 12 mg doses. Suboxone is an office-based treatment used to treat opioid dependence, ...
Tags: Suboxone Tablets, office-based treatment, opioid dependence